Gisbert Schneider is a full professor at ETH Zurich, holding the Chair for Computer-Assisted Drug Design, and the Associate Vice President for ETH Global. His research focuses on the integration of artificial intelligence into practical medicinal chemistry. His career has led him from the Pharmaceuticals Division at Roche, Basel, to academia, initially to the Goethe-University in Frankfurt where he held the Beilstein Endowed Chair for Chem- and Bioinformatics, and then to his current position at ETH in Zurich. He is an elected Fellow of the University of Tokyo, and the recipient of the 2018 Herman Skolnik Award for his contributions to de novo design of bioactive compounds. He has co-founded several start-up companies including inSili.com LLC, AlloCyte Pharmaceuticals AG, and Endogena Therapeutics Inc.